Leerink Partnrs Has Pessimistic View of Vaxcyte Q1 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Analysts at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for shares of Vaxcyte in a research note issued to investors on Tuesday, April 1st. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of ($1.07) per share for the quarter, down from their prior forecast of ($1.01). The consensus estimate for Vaxcyte’s current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte’s Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.37) EPS, FY2025 earnings at ($4.85) EPS, FY2026 earnings at ($5.50) EPS, FY2027 earnings at ($5.59) EPS, FY2028 earnings at ($4.68) EPS and FY2029 earnings at $0.46 EPS.

PCVX has been the subject of a number of other research reports. Bank of America decreased their target price on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research report on Tuesday. The Goldman Sachs Group decreased their price objective on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a report on Tuesday. Needham & Company LLC cut their target price on Vaxcyte from $140.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday. Guggenheim reaffirmed a “buy” rating and set a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, Evercore ISI raised Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $136.50.

Vaxcyte Trading Up 3.4 %

PCVX opened at $31.60 on Thursday. The business’s 50 day moving average is $74.59 and its 200-day moving average is $89.85. The stock has a market cap of $4.07 billion, a PE ratio of -6.87 and a beta of 1.26. Vaxcyte has a twelve month low of $29.57 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14.

Insider Transactions at Vaxcyte

In related news, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. This represents a 46.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total transaction of $689,760.00. Following the transaction, the chief operating officer now owns 205,695 shares in the company, valued at approximately $17,735,022.90. The trade was a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,250 shares of company stock valued at $3,170,738 over the last three months. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors have recently bought and sold shares of the business. Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte during the fourth quarter worth approximately $28,000. Smartleaf Asset Management LLC boosted its stake in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after buying an additional 260 shares during the period. National Bank of Canada FI purchased a new position in shares of Vaxcyte during the 4th quarter valued at $41,000. Blue Trust Inc. increased its stake in shares of Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after acquiring an additional 371 shares during the last quarter. Finally, Assetmark Inc. raised its holdings in shares of Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after acquiring an additional 775 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.